Trials / Unknown
UnknownNCT04866108
A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy
A Single Center, Open-labeled, Single Arm Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center, open-labeled, single arm phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients unsuitable for intravenous chemotherapy.
Detailed description
Fruquintinib is an oral small molecule inhibitor of VEGFR1/2/3, this phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients of elderly or those unsuitable for intravenous chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fruquintinib plus capecitabine | oral fruquintinib plus capecitabine |
Timeline
- Start date
- 2021-12-08
- Primary completion
- 2024-06-01
- Completion
- 2024-06-01
- First posted
- 2021-04-29
- Last updated
- 2022-08-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04866108. Inclusion in this directory is not an endorsement.